Study to Compare Milk Protein Isolate (MPI) With Caseinate in Terms of Protein Utilization

University College Cork (UCC)

Status and phase: Completed; Phase 3; Phase 2

Conditions: Enteral Feeds

Treatments: Dietary Supplement: Caseinate; Dietary Supplement: Milk Protein Isolate

Study type: Interventional

Funder types: Other

Identifiers

NCT01599988

APC032

Details and patient eligibility

About

The Clinical Research Ethics Committee, Cork comprises of faculty representatives, external representatives, legal representatives and appropriate individuals and ex-officio administrative members with needed expertise. Ethics Committee members, including the Chair, are appointed by the Head of College, University College Cork, Medical School.

The Ethics Committee meets once a month.

Enrollment: 24 patients

Sex: All

Ages: 65 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

To be considered eligible for enrolment into the study, subjects must;

1. Be able to give written informed consent.
2. Be between 65 and 75 years of age.
3. Be in generally good health as determined by the investigator.
4. Have no evidence of gastrointestinal disease or of a functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.
5. Have a stable body weight over the past 3-months.
6. Have a Body Mass Index (BMI) greater than 22, for males and 20 for females and less than 30.
7. Have a satisfactory nutritional status.

Exclusion criteria

Subjects will be excluded from the study if they meet any of the below criteria;

1. Are less than 65 and greater than 75 years of age.
2. Have evidence of gastrointestinal disease or other functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.
3. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgement, entry to the study).
4. Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include anti-inflammatory drugs, corticosteroids, laxatives, enemas, antibiotics (within 1 month), anti-coagulants, and over-the counter non-steroidal analgesics. Subjects should have a wash-out period of two-weeks.
5. Be a smoker.
6. Consume more than the recommended alcohol guidelines i.e. 3-4 alcohol units a day for a man and for a woman 2-3 units a day.
7. Suffer from psychiatric disease
8. Prior gastrointestinal surgery (apart from appendicectomy and hernia repair) or recent unexplained bleeding.
9. Have dietary habits (slimming or vegetarian diet) which could interfere with the assessment of the study product.
10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
11. Subjects may not be receiving treatment involving experimental drugs.
12. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
13. Have a malignant disease or any concomitant end-stage organ disease

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

24 participants in 2 patient groups

Milk protein isolate

Active Comparator group

Description:

The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.

Treatment:

Dietary Supplement: Milk Protein Isolate

Caseinate

Active Comparator group

Description:

The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.

Treatment:

Dietary Supplement: Caseinate